Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may ...
Boston Scientific is capping off a busy week with a major buyout, entering a deal worth around $14.5 billion to acquire ...
Hopes were high Wednesday for a billion-dollar mega-deal—the kind the J.P. Morgan Healthcare Conference is known for—but no ...
Italian pharma Alfasigma has penned a 125 million euro ($145 million) deal for the rights to an injectable form of an investigational herpes simplex virus (HSV) encephalitis treatment. | Italian ...
Charles River Laboratories has struck a $510 million deal to buy a non-human primate provider, furthering efforts to ...
The bispecific antibody—which targets the IL-23p19 and TL1A pathways—was licensed from China’s Qyuns Therapeutics. Since ...
The Novo Nordisk Foundation is investing 5.5 billion Danish kroner ($860 million) in the BioInnovation Institute (BII) to help scale up more homegrown biotechs and deep tech companies. | The Novo ...
Looking to usher in a more “predictable” year in 2026, Illumina is working with officials in China as it remains on the ...
Still riding the high of last year’s twice-yearly HIV PrEP approval of lenacapavir as Yeztugo, Gilead Sciences is approaching ...
The J.P. Morgan Healthcare Conference, as well as Fierce's own JPM Week, roll into Wednesday with plenty more events, ...
After a busy first day featuring headlines from a who's who of leading biopharma companies, the J.P. | The J.P. Morgan ...
Lyra Therapeutics is abandoning work on its rhinosinusitis treatment and laying off its remaining employees.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results